From: Dilemmas and options for COVID-19 vaccination in children
Variant | Years | Vaccination status | Type of vaccination | Detection time interval | Vaccine effectiveness (95% CI) | Reference | ||
---|---|---|---|---|---|---|---|---|
Symptomatic infection | Hospital admission | Admission ICU | ||||||
Omicron | 5–11 | First dose | BNT162b2 | 14–27 days | 18.0% | NP | [55] | |
≥ 14 days | 9.0% | [56] | ||||||
Second dose | ≥ 7 days | 49.0% | ||||||
14–30 days | 60.1% | [57] | ||||||
30–90 days | 28.9% | |||||||
≥ 7 days | NP | 82.7% | NP | [58] | ||||
≥ 14 days | 68.0% | [59] | ||||||
7–21 days | 48.0% | NP | [55] | |||||
51 days (median) | NP | 48.0% | NP | [60] | ||||
0–14 days | 38.7% | NP | [61] | |||||
43–84 days | 21.2% | |||||||
Omicron | 12–18 | First dose | BNT162b2 | 122 days (median) | 26.1% | NP | [62] | |
CoronaVac | 31 days (median) | 21.5% | ||||||
Second dose | BNT162b2 | 189 days (median) | 54.9% | |||||
CoronaVac | 64 days (median) | 55.0% | ||||||
BNT162b2 | 2–22 weeks | NP | 43.0% | NP | [59] | |||
23–44 weeks | 38.0% | |||||||
Pre-Omicron | 2–22 weeks | 93.0% | ||||||
23–44 weeks | 92.0% | |||||||
7–21 days | 93.0% | NP | [63] | |||||
≥ 14 days | NP | 94.0% | 98.0% | [64] | ||||
62 days (median) | 93.0% | NP | [65] | |||||
Omicron | Third dose | BNT162b2 | 31 days (median) | 86.8% | NP | [62] | ||
CoronaVac | 67 days (median) | 92.0% |